HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World data to show if HAE drug works in kids
Disease control Recruiting nowThis study tracks 40 children aged 2 to 12 with hereditary angioedema (HAE) who are taking lanadelumab to prevent sudden, painful swelling attacks. Researchers will look at medical records to see how long kids stay attack-free and how the drug performs in daily life. No new treat…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New RNA drug shows promise in preventing HAE attacks in ongoing study
Disease control Recruiting nowThis study is for people with hereditary angioedema (HAE) who have already completed a previous trial of the drug ADX-324. ADX-324 is an RNA-based medicine designed to lower a protein involved in swelling attacks. The goal is to see if long-term use is safe and can reduce the num…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with rare swelling disorder as drug trial begins
Disease control Recruiting nowThis study tests a drug called donidalorsen in 20 children aged 2 to 12 with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and how it works in young bodies. Researchers will monitor side effects and measure h…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New daily pill could stop debilitating swelling attacks in HAE patients
Disease control Recruiting nowThis Phase 3 study tests a once-daily pill called deucrictibant to prevent swelling attacks in people aged 12 and older with hereditary angioedema (HAE). The trial will enroll 170 participants and monitor safety and attack rates over a long period. Unlike a cure, patients would n…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising HAE prevention drug now available for kids in Follow-Up study
Disease control AVAILABLEThis study offers children aged 2 to 11 with hereditary angioedema (HAE) continued access to garadacimab, a lab-made antibody that helps prevent sudden, painful swelling attacks. Participants must have completed a prior study and shown good response with few or no attacks. The go…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 26, 2026 15:01 UTC
-
Could a single blood test speed up HAE diagnosis?
Diagnosis Recruiting nowThis study looks at whether measuring just one protein function (C1-inhibitor) can accurately diagnose hereditary angioedema (HAE), a rare condition causing sudden swelling. About 514 people in Algeria who are suspected of having HAE or have family members with it will take part.…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: NA • Sponsor: Takeda • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Real-World data: does takhzyro stop HAE swelling in saudi patients?
Knowledge-focused Recruiting nowThis study looks back at medical records of 50 people in Saudi Arabia with hereditary angioedema (HAE) who took Takhzyro (lanadelumab) to prevent attacks. Researchers want to see if the drug reduces HAE activity and improves quality of life after 6 to 12 months. No new treatments…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC